ESSA Pharma Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Sep 30, 2024	FY2023 12 months to Sep 30, 2023	FY2022 12 months to Sep 30, 2022	FY2021 12 months to Sep 30, 2021	FY2020 12 months to Sep 30, 2020
OPERATING EXPENSES
Research and development
Financing costs
General and administration
Total operating expenses
Foreign exchange
Interest income
Investment and other income
Derivative liability gain (Note 8)
Loss for the year before taxes
Income tax expense (Note 10)
Net loss for the year
Basic and diluted loss per common share
Weighted average number of common shares outstanding - basic and diluted
OTHER COMPREHENSIVE INCOME
Unrealized gain on short-term investments (Note 4)
Loss and comprehensive loss for the year
Earnings Per Share
Basic loss per common share (in dollars per share)
Diluted loss per common share (in dollars per share)
Weighted average number of common shares outstanding - Basic (in shares)
Weighted average number of common shares outstanding -Diluted (in shares)

Comments